Antiviral drugs are the type of medication used for the treatment of viral infections. A huge number of antivirals target specific viruses, while a broad-spectrum antiviral is productive in front of a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead, they inhibit its development. Antiviral therapy aims to minimize symptoms and infectivity as well as to shorten the duration of illness. Several respiratory viral infections continued to be the most important threat to human health because of the similar clinical symptoms. However, different pathogens, sensitive and rapid diagnosis are needed for early identification of viral with cost-effective monitoring during clinical trials. Most antiviral drugs now available are designed to help deal with HIV, herpes viruses, the hepatitis B & C viruses, influenza A & B viruses, and Covid-19. After that, the development of cost-effective, broad-spectrum antiviral agents is an urgent mission for both virologists and pharmacologists.
The global respiratory antivirals market is expected to gain market growth in the forecast period of 2020-2027. The major factors are the growing demand for viral diagnostics tools, systems, equipment & kits, and vaccinations to prevent viral infection. Additionally, the increasing utilization of different kinds of viral detection kits such as RT-PCR or nucleic acid detection kit and bioanalytical assays. Highly sensitive, reliable, and efficient will spur the global respiratory antivirals industry in the future periods. Furthermore, the increasing incidents of respiratory infections, technological advancement, and increasing health care expenditure are expected to witness remarkable growth of respiratory antivirals. The increasing government initiative and rise in awareness of viral infections among people to treat viral diseases are expected to propel the demand for the respiratory antivirals treatment industry over the forecast period.
Moreover, the upsurge in demand for therapeutics for respiratory illness and antiviral drugs positively impacts the market for respiratory antivirals in the health care & pharmaceutical industry. Furthermore, the rapidly rising R&D activities at the academic and industrial level and growing viral infections fuel the demand for the respiratory antiviral market. The rising awareness towards the availability of vaccinations across the globe acts as a restraint to the market growth of antiviral drugs.
Most of the antiviral drugs now available and are designed to help deal with viruses such as ebolavirus (EBOV), Hendra virus (HEV), and Nipah virus (NiV) but are of limited use in treating a patient who has already been infected. It is also difficult to successfully deploy them against rapidly mutating viruses, such as influenza and HIV. Due to these increasing disorders, many pharmaceutical industries are stepping forward to develop new DNA-based or plant-based vaccines. Moreover, due to the advantages of large market size, increasing viral illness, and gradual maturity of technology applications, antivirals have attracted various enterprises to the layout. Additionally, the manufacturing process’s surge for a wide range of test kits, such as antibody tests, PCR tests, self-administered, and others, will enhance the demand for antivirals in the healthcare industry.
Based on the disease type, the global respiratory antivirals market is segregated into upper respiratory tract infections, influenza, bronchiolitis, pneumonia, measles, croup, and others. The upper respiratory tract infections (RTI) segment is estimated to witness the highest growth over the analysis timeframe due to the rising patient population. It is the most common reason for the doctor visit and resulting in missed school &work.
The influenza segment is poised to witness significant growth over the forecast period due to the rising rate of the flu virus and increases in health care provider visits for acute respiratory illness, including influenza A & B.
Based on the drug class, the global respiratory antivirals market is categorized into neuraminidase inhibitors, nucleoside analogs, fusion protein inhibitors, and ion channel blockers. The nucleoside analogs segment is further divided into ribavirin, acyclovir, and others, and the neuraminidase inhibitors segment has been sub-divided into oseltamivir zanamivir and so many others. The neuraminidase inhibitors segment is anticipated to dominate/reduce the global respiratory antiviral treatment market during the forecast period due to increasing illnesses such as influenza A and influenza B and their effectiveness in reducing cases and deaths.
The Nucleoside Analogs segment is poised to witness significant growth over the forecast period, including ribavirin and aciclovir. They effectively prevent hepatocellular carcinoma in hepatitis B with long-term protective effects among chronic hepatitis B patients.
By geography, the global respiratory antivirals market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The Asia Pacific is estimated to project considerable growth over 2020-2026. It is owing to rising patients of viral infections with rising demand for therapeutics, advents in technology, the presence of leading industry players offering innovative products, and increasing healthcare expenditure.
Europe will capture a prominent share of the respiratory antivirals market by 2027. It is due to the continually improving healthcare infrastructure in the region and mounting health care expenditures.
Companies such as GlaxoSmithKline plc, AbbVie; Merck & Co, Johnson & Johnson, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan Inc, and AstraZeneca plc are the key players in the global respiratory antivirals market.
By Disease Type
By Drug Class